linjc16/ctgov huggingface dataset:
Risk Level of Suffering From Traffic Injury in Primary Health Care: LESIONAT Project

Study Overview
=================
Brief Summary
-----------------
Main objectives: To know the distribution of risk elements of traffic injuries Secondary objectives: To study the distribution of risk elements related with the possibility of suffering from a TI in relation to medication, chronic health problems, and consumption of psychoactive substances (alcohol and others). To know the relation between levels of perception of risk of suffering from a TI and the presence of chronic problems, medications, or consumption of psychoactive substances.

Detailed Description
-----------------
Methodology: Design: Observational, transversal, and multicentric research Field of study: 20 PHC users from urban areas Population of study: random consecutive sampling of ≥ 16 years old drivers with open medical history. Measure's tools: Two means for data collection: survey among health professionals with medical history and structured telephonic survey about behaviours and risk perceptions in drivers. Variables: Sociodemographic data, chronic pathologies related to TI, consumption of medications ,Alcohol consumption (AUDIT-C test), Psychoactive substances consumption (self declared), Level of perception of risk according to professionals. Telephone survey: Class and age of driving license, Type of roads, Weekly driving time, Safety behaviours, Record of collisions/injuries in last year,Self perception of health level(SF-12) andSelf perception of risk level. An descriptive analysis of population will be performed, a distribution of risk elements associated to TI will be described through bivariant analyses, and for describing the factors associated to perceived risk levels a linear regression multiple model will be built.

Official Title
-----------------
Risk Level of Suffering From Traffic Injury in Primary Health Care: LESIONAT Project

Conditions
-----------------
Traffic Accident, Chronic Disease, Prevalence of Psychoactive Substances in Road Traffic, Relative Risk Estimation of Accident for Impaired Drivers

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 16 years old or more Catalan and/or spanish language speakers Drivers with driver license Participation accepted by the patient Exclusion Criteria: Patients who do not have contact phone number. Patients who do not answer up to 3 phone calls Patients with severe mental or physical health disorder

Ages Eligible for Study
-----------------
Minimum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Injuries, Traffic Injuries, Preventive medicine, Observational studies, Primary care
Idiopathic Scoliosis and Orthodontic Treatment

Study Overview
=================
Brief Summary
-----------------
Scoliotic pathology remains to this day little known, on the one hand in its etiologies but also in its various implications and possible associations. One of the notable questions found in the literature is concerned with the link between idiopathic scoliosis and the stomatognathic system. This question arises from the study of the anatomy and function of its two entities. The aim of the study is to determine the frequency of orthodontic treatment in adolescents with idiopathic scoliosis, and to compare it with that of adolescents without spinal dysmorphism.

Official Title
-----------------
Idiopathic Scoliosis and Orthodontic Treatment

Conditions
-----------------
Idiopathic Scoliosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Adult and child (age ≥ 12 years) Be carriers of idiopathic scoliosis confirmed by X-ray. Have reached bone maturity (Risser 4 and more) Adult who has not expressed, after information, the reuse of his data for the purposes of this research - Child and Holders of parental authority who have not expressed, after information, the reuse of their data for the purposes of this research Exclusion criteria: Refusal to participate in the study Association with another orthopedic pathology Adult patients under guardianship or crater or under the protection of justice

Ages Eligible for Study
-----------------
Minimum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Determination of the frequency of wearing orthodontic treatment in idiopathic scoliosis adolescents, and compare it with that of adolescents without spinal dysmorphism. |  | Files analysed retrospectively from January 01, 2020 to August 31, 2020 will be examined] | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Idiopathic scoliosis, Orthodontic Treatment, spinal dysmorphism
An Electronic Personal Health Record for Mental Health Consumers

Study Overview
=================
Brief Summary
-----------------
Electronic Personal Health Records (PHRs) hold promise in helping reshape healthcare by shifting the ownership and locus of health records from being scattered across multiple providers to an approach that is longitudinal and patient-centered. Given the complex health needs and the fragmentation of care for persons with serious mental illnesses, these individuals could derive particular benefit from a PHR. However, there are currently no established PHRs developed for use in this population. In order to fill this gap, the investigators propose to develop, test, and disseminate a Personal Health Record for persons with serious mental illnesses and one or more comorbid medical condition. The Mental Health PHR (MH-PHR) builds on an established personal health record which was developed in partnership with medical consumers and is in wide use in a number of communities in the United States and abroad.

Official Title
-----------------
An Electronic Personal Health Record for Mental Health Consumers

Conditions
-----------------
Chronic Comorbid Conditions

Intervention / Treatment
-----------------
* Other: personal electronic medical record


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Currently in treatment at the CMHC. Serious Mental Illness: based on or chart review; One or more Chronic Medical Condition as ascertained via administrative records.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Case<br>Assigned a Personal Electronic Health Record | Other: personal electronic medical record<br> <br> |
| Active Comparator: Control: Usual Care<br>Assigned to control arm, continued to receive care as usual in community. Was issued information on community health resources, but did not use research study personal health record. | Other: personal electronic medical record<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of Care |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
serious mental illness
Benazepril for Advanced Chronic Renal Insufficiency

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to further determine whether benazepril, could safely slow the progression of renal dysfunction in non-diabetic patients with advanced renal insufficiency.

Conditions
-----------------
Chronic Kidney Failure

Intervention / Treatment
-----------------
* Drug: Benazepril


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: serum creatinine concentration 1.5-5.0 mg/dL (133-442 µmol/L) creatinine clearance 20 to70 mL/min/1.73 m2, with variations of less than 30 percent in the three months before the screening evaluation non-diabetic renal disease persistent proteinuria (defined as urinary protein excretion greater than 0.3 g/day for three or more months without evidence of urinary-tract infection or overt heart failure [New York Heart Association class III-IV]). Exclusion Criteria: immediate need for dialysis; treatment with corticosteroids, non-steroidal anti-inflammatory drugs or immunosuppressive drugs; renovascular disease; myocardial infarction or cerebrovascular accident in the year preceding the trial; connective-tissue disease; obstructive uropathy.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Benazepril|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Advanced Chronic Renal Insufficiency, Benazepril
Is Preoperative Exercise Test in Morbid Obese Patients a Predictive Test for Extubation?

Study Overview
=================
Brief Summary
-----------------
the purpose of this study is to determine if 60 meter test done prior to surgery is a predictive in terms of extubation in morbid obese patients undergoing morbid obese surgery.

Official Title
-----------------
Is Preoperative Exercise Test in Morbid Obese Patients Undergoing Laparoscopic Sleeve Gastrectomy a Predictive Test for Extubation?

Conditions
-----------------
Morbid Obesity

Intervention / Treatment
-----------------
* Other: walk test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients between 18-60 years old patients with BMI > 40 patients undergoing Laparoscopic Sleeve Gastrectomy Exclusion Criteria: patients with Chronic obstructive pulmonary disease (COPD), Asthma, patients with uncompensated heart failure Uncompensated diabetes mellitus Patients Who have orthopedic problems that effects the exercise test

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: walk test<br>morbid obese patients (BMI>40) undergoing laparoscopic sleeve gastrectomy walking 60 meters under 1 minute before and after the measurement of Forced vital capacity (FVC) | Other: walk test<br>* patients will be encouraged to walk a 60 meter distance under 1 minute and FVC will be measured before and after the walk test<br>* Other names: 60 meter walk test;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants with successful extubation | preoperative 60 meter walk test | postoperative 30 minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
morbid obesity surgery, walk test, exercise
Gingival Crevicular Fluid Alkaline Phosphatase as Skeletal Growth Indicator

Study Overview
=================
Brief Summary
-----------------
Determination of the pubertal growth spurt in Egyptian female patients using gingival crevicular fluid alkaline phosphatase

Detailed Description
-----------------
assessment of the pubertal growth spurt in growing Egyptian female patients by using a simple, quick and easy method, through taking a gingival crevicular fluid alkaline phosphatase sample and measuring its concentration. Comparing the concentration of GCF ALP to the standardized middle phalanax of the middle finger MP3 we can predict if it can be an accurate and reliable method as skeletal growth indicator.

Official Title
-----------------
Gingival Crevicular Fluid Alkaline Phosphatase Activity as a Biomarker of Skeletal Maturation in Comparison to Modified Middle Phalanx of The Middle Finger (MP3) Method in a Sample of Growing Egyptian Females

Conditions
-----------------
Growth Indictaor

Intervention / Treatment
-----------------
* Radiation: periapical xray


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Gender: only female subjects will be included. Age between 7-16 years old Intermediate or late mixed dentition and permanent dentition Good general health with absence of any nutritional problems or bony disease No usage of any anti-inflammatories or antibiotics in the month preceding the study Fully erupted upper and lower central incisors for sample collection Good gingival and periodontal health as indicated by Probing depth (PD) values that should not exceed 3 mm for the whole dentition. Willingness to participate in the study and sign the informed consent form Exclusion Criteria: Male adolescent subjects Periodontal and /or gingival disease Systemic and/or bone disease 3. Growth abnormality

Ages Eligible for Study
-----------------
Minimum Age: 7 Years
Maximum Age: 16 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| prepubertal<br>patients born in 2012-2011 | Radiation: periapical xray<br>* periapical xray on the middle phalanax of the middle finger<br>|
| pubertal<br>patients born in 2010-2009-2008-2007 | Radiation: periapical xray<br>* periapical xray on the middle phalanax of the middle finger<br>|
| postpubertal<br>patients born in 2006-2005-2004-2003 | Radiation: periapical xray<br>* periapical xray on the middle phalanax of the middle finger<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| GCF ALP concentration | concentration of gingival crevicular fluid alkaline phosphatase | immediately after sample collection | 
| MP3 | periapical x-ray of the middle phalanax of the middle finger | immediately after taking x-rays |
Family Risk Analysis of Substance Use in Attention Deficit Hyperactivity Disorder (ADHD) Youth Treated With Concerta

Study Overview
=================
Brief Summary
-----------------
The researchers will study 100 families over three years, each with a child (proband) between the ages of 12-17, with the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) diagnosis of ADHD. The researchers hypothesize smoking will be familial and ADHD probands with a family history of tobacco use will be at increased risk for early initiation and persistence of smoking, compared to ADHD probands with no family history of tobacco use.

Detailed Description
-----------------
As Attention Deficit Hyperactivity Disorder (ADHD) is a documented risk factor for smoking in adolescents, and as theoretical considerations suggest that ADHD and tobacco use may share common underlying mechanisms, the proposed study looks to examine the association between smoking and ADHD. Since both ADHD and smoking are known to be familial disorders, one approach to examine the nature of the association between the two disorders is to conduct a familial risk analysis comparing ADHD youth who smoke and ADHD youth who don't smoke. Another approach is to conduct a genetic study, to identify candidate genes associated with nicotine abuse and dependence in ADHD youth and relatives. This study includes: assessment of psychopathology and substance use/dependence, assessment of the family environment, and assessment of molecular genetics in 100 families with at least one child (proband) between the ages of 12-17 with a DSM-IV diagnosis of ADHD.

Official Title
-----------------
Family Risk Analysis of Substance Use in ADHD Youth Treated With Concerta

Conditions
-----------------
ADHD, Smoking

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: First-degree relative between the ages of 6-55 years of a family member (proband) between the ages of 12-17 with the DSM-IV diagnosis of ADHD

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ADHD, smoking, familial risk
Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fasted Conditions

Study Overview
=================
Brief Summary
-----------------
The objective of this study was to prove the bioequivalence of Roxane Laboratories' Oxcarbazepine Suspension 600 mg under fasted conditions.

Official Title
-----------------
A Single Dose, Two-Period, Two-Treatment, Two-Sequence Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fasted Conditions

Conditions
-----------------
Seizures

Intervention / Treatment
-----------------
* Drug: Oxcarbazepine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening Exclusion Criteria: Positive test for HIV, Hepatitis B, or Hepatitis C. Treatment with known enzyme altering drugs. History of allergic or adverse response to oxcarbazepine or any comparable or similar product.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Oxcarbazepine first, then Trileptal<br>Single dose of oxcarbazepine suspension, 600 mg, then single dose of trileptal suspension, 600 mg (after washout period) | Drug: Oxcarbazepine<br> <br> * Other names: Trileptal;|
| Active Comparator: Trileptal first, then Oxcarbazepine<br>Single dose of oxcarbazepine suspension, 600 mg, then single dose of trileptal suspension, 600 mg (after washout period | Drug: Oxcarbazepine<br> <br> * Other names: Trileptal;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| bioequivalence determined by statistical comparison Cmax |  | 10 Days |
fMRI in Deep Brain Stimulation

Study Overview
=================
Brief Summary
-----------------
With fMRI, we want to understand the mechanisms of brain neuromodulation in (dys)functional brain circuits, to obtain knowledge on involved brain networks in DBS.

Detailed Description
-----------------
Deep brain stimulation represents a neurosurgical treatment option for specific refractory neurological and psychiatric disorders. In these patients a specific brain target is stimulated through an electrode with the use of an implantable pulse generator (IPG). In a functional MRI (fMRI) experiment, the investigators intend to perform imaging during stimulation ON and compare brain activations with the stimulation OFF condition. In this way, they aim to elucidate the involved brain network in deep brain stimulation. Since the connectivity of deep brain structures is complex, different activation patterns are expected in-between subjects and conditions. If specific activation patterns during the stimulation ON condition can be related to treatment response, this is of important clinical value. These findings can lead to an optimization of the deep brain target or even to different useful targets for brain stimulation.

Official Title
-----------------
Functional Magnetic Resonance Imaging in Deep Brain Stimulation

Conditions
-----------------
Epilepsy, Chronic Pain

Intervention / Treatment
-----------------
* Diagnostic Test: fMRI


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Deep brain stimulation system implanted Exclusion Criteria: Children and pregnant women will be excluded. Failure to follow to protocol is also an exclusion criterion.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Intervention Model: Single Group Assignment
Interventional Model Description: For each subject, condition effects will be estimated using the general linear model
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: fMRI intervention<br> | Diagnostic Test: fMRI<br>* Functional MRI will be performed in 1 scan, which will take 1.5 h. (scanning time = 30 min)<br>* Other names: DBS;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Determine the functional networks that are involved in DBS | To determine differences in activations of functional networks between ON and OFF DBS in an fMRI experiment, | 5 years | 
| To link the involved network to outcome in DBS therapy | To link specific activation patterns during ON-OFF with a clinical value | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
fMRI, epilepsy, pain, electrode, brain, neuromodulation, DBS